1
|
SIRT5 reduces the inflammatory response and barrier dysfunction in IL-17A-induced epidermal keratinocytes. Allergol Immunopathol (Madr) 2023; 51:30-36. [PMID: 36617819 DOI: 10.15586/aei.v51i1.675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 06/20/2022] [Indexed: 01/04/2023]
Abstract
Psoriasis is a chronic multisystemic inflammatory disease with inflammatory cell infiltration, hyperproliferation of keratinocytes in skin lesions, and epidermal barrier dysfunction. Normal human epidermal keratinocytes (NHEKs) were stimulated with interleukin 17A (IL-17A). The expression levels of sirtuin-5 (SIRT5) were analyzed by RT-qPCR and western blot assay. The proliferation levels of NHEKs were assessed by EdU staining. The expression of ELOVL1 and ELOVL4 was analyzed by RT-Qpcr, and the expression levels of filaggrin, loricrin, and aquaporin-3 were analyzed by RT-qPCR and western blot. Extracellular signal-regulated kinase 1/2 (ERK1/2) activator t-butylhydroquinone was used to activate ERK1/2. Here, we show that SIRT5 overexpression reduces cell viability and cell proliferation, and improves barrier dysfunction in IL-17A-treated human epidermal keratinocytes, this effect of which is significantly blunted by the ERK1/2 activator. In epidermal keratinocytes, SIRT5 decreases cell proliferation and inflammation and improves barrier dysfunction via ERK/STAT3. This study reveals the role of SIRT5 in the pathogenesis of psoriasis, epidermal hyperplasia, keratinocyte-mediated inflammatory responses, and barrier dysfunction, the role of which is mediated by ERK/STAT3.
Collapse
|
2
|
Montero-Vilchez T, Soler-Góngora M, Martínez-López A, Ana FG, Buendía-Eisman A, Molina-Leyva A, Arias-Santiago S. Epidermal barrier changes in patients with psoriasis: The role of phototherapy. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 2021; 37:285-292. [PMID: 33377542 DOI: 10.1111/phpp.12650] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Accepted: 12/25/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND Some skin diseases may modify epidermal barrier function. Psoriasis is a chronic multi-systemic inflammatory disease that affects the epidermal barrier. Phototherapy is an option for treating psoriasis, but little is known about how epidermal barrier function is modified by phototherapy in psoriatic patients. OBJECTIVES (a) To compare skin homeostasis between involved and uninvolved skin in psoriatic patients with healthy controls (b) To evaluate changes in the epidermal barrier function in psoriatic patients treated with phototherapy. METHODS Sixty patients with plaque-type psoriasis and sixty gender and age-matched healthy controls were enrolled. Temperature, transepidermal water loss (TEWL), stratum corneum hydration (SCH), pH, elasticity, erythema and melanin index were measured using non-invasive tools in the healthy control and involved and uninvolved psoriatic skin before and after phototherapy. RESULTS Healthy controls had lower TEWL and erythema index and higher SCH than psoriatic patients, both at uninvolved psoriatic skin and psoriasis plaques. TEWL was higher at psoriasis plaques than at uninvolved skin (19.20 vs 11.57 g/h/m2 ; P < .001). Following phototherapy, a decreasing trend was observed for TEWL, of 1.03 (SD 0.75) and 0.97 (SD 0.81) g/h/m2 for uninvolved and involved skin respectively. SCH was significantly lower at psoriatic plaques than at uninvolved skin (7.32 vs 36.62Arbitrary Units [AU]; P < .001). SCH increased by 1.15AU (SD 0.26) on psoriatic plaques after the phototherapy session (P < .001). CONCLUSION Psoriatic plaques showed epidermal barrier dysfunction compared to uninvolved skin and healthy controls. Phototherapy may improve epidermal barrier function in psoriatic patients. SCH increased after a phototherapy session on the psoriatic plaques.
Collapse
Affiliation(s)
- Trinidad Montero-Vilchez
- Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.,Instituto de Investigación Biosanitaria IBS, Granada, Spain
| | - Miguel Soler-Góngora
- Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - Antonio Martínez-López
- Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.,Instituto de Investigación Biosanitaria IBS, Granada, Spain
| | | | | | - Alejandro Molina-Leyva
- Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.,Instituto de Investigación Biosanitaria IBS, Granada, Spain
| | - Salvador Arias-Santiago
- Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.,Instituto de Investigación Biosanitaria IBS, Granada, Spain.,Dermatology Department, Faculty of Medicine, University of Granada, Granada, Spain
| |
Collapse
|
3
|
Darlenski R, Hristakieva E, Aydin U, Gancheva D, Gancheva T, Zheleva A, Gadjeva V, Fluhr JW. Epidermal barrier and oxidative stress parameters improve during in 311 nm narrow band UVB phototherapy of plaque type psoriasis. J Dermatol Sci 2018; 91:28-34. [DOI: 10.1016/j.jdermsci.2018.03.011] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Revised: 03/05/2018] [Accepted: 03/19/2018] [Indexed: 11/25/2022]
|
4
|
Wegienka G, Sitarik A, Bassirpour G, Zoratti EM, Ownby D, Johnson CC, Havstad S. The associations between eczema and food and inhalant allergen-specific IgE vary between black and white children. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2017; 6:292-294.e2. [PMID: 28958743 DOI: 10.1016/j.jaip.2017.07.037] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 07/11/2017] [Accepted: 07/25/2017] [Indexed: 12/26/2022]
Affiliation(s)
- Ganesa Wegienka
- Department of Public Health Sciences, Henry Ford Health System, Detroit, Mich; International Inflammation (in-FLAME) Network, Worldwide Universities Network (WUN), West New York, NJ; Center for Urban Responses to Environmental Stressors, Detroit, Mich.
| | - Alexandra Sitarik
- Department of Public Health Sciences, Henry Ford Health System, Detroit, Mich
| | - Gillian Bassirpour
- Division of Allergy and Clinical Immunology, Henry Ford Health System, Detroit, Mich
| | - Edward M Zoratti
- Division of Allergy and Clinical Immunology, Henry Ford Health System, Detroit, Mich
| | - Dennis Ownby
- Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Ga
| | - Christine C Johnson
- Department of Public Health Sciences, Henry Ford Health System, Detroit, Mich; International Inflammation (in-FLAME) Network, Worldwide Universities Network (WUN), West New York, NJ; Center for Urban Responses to Environmental Stressors, Detroit, Mich
| | - Suzanne Havstad
- Department of Public Health Sciences, Henry Ford Health System, Detroit, Mich
| |
Collapse
|
5
|
Ardern-Jones M, Bieber T. Biomarkers in atopic dermatitis: it is time to stratify. Br J Dermatol 2014; 171:207-8. [DOI: 10.1111/bjd.13210] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- M.R. Ardern-Jones
- Clinical & Experimental Sciences Division; Department of Dermatology; Southampton General Hospital; University of Southampton; Southampton SO16 6YD U.K
| | - T. Bieber
- Department of Dermatology and Allergy; University of Bonn; Sigmund Freud Straße 25 53105 Bonn Germany
| |
Collapse
|
6
|
Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M, Heinz V, Kreilinger D, Spielberger BD, Schimke-Marques LF, Sawalle-Belohradsky J, Belohradsky BH, Przybilla B, Schaub B, Wollenberg A, Renner ED. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014; 69:943-53. [PMID: 24898675 DOI: 10.1111/all.12416] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/21/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Increased serum IgE levels are characteristic but not specific for allergic diseases. Particularly, severe atopic dermatitis (AD) overlaps with hyper-IgE syndromes (HIES) regarding eczema, eosinophilia, and increased serum IgE levels. HIES are primary immunodeficiencies due to monogenetic defects such as in the genes DOCK8 and STAT3. As it is not known to date why allergic manifestations are not present in all HIES entities, we assessed the specificity of serum IgE of AD and HIES patients in the context of clinical and immunological findings. METHODS Clinical data, skin prick tests, specific IgE to aero- and food allergens, and T helper (Th) subpopulations were compared in AD and molecularly defined HIES patients. RESULTS Total serum IgE levels were similarly increased in STAT3-HIES, DOCK8-HIES, and AD patients. The ratio of aeroallergen-specific IgE to total IgE was highest in AD, whereas DOCK8-HIES patients showed the highest specific serum IgE against food allergens. Overall, clinical allergy and skin prick test results complied with the specific IgE results. Th2-cell numbers were significantly increased in DOCK8-HIES and AD patients compared to STAT3-HIES patients and controls. AD patients showed significantly higher nTreg-cell counts compared to STAT3-HIES and control individuals. High Th17-cell counts were associated with asthma. Specific IgE values, skin prick test, and T-cell subsets of STAT3-HIES patients were comparable with those of healthy individuals except decreased Th17-cell counts. CONCLUSION Hyper-IgE syndromes and atopic dermatitis patients showed different sensitization pattern of serum IgE corresponding to the allergic disease manifestations and Th-cell subset data, suggesting a key role of DOCK8 in the development of food allergy.
Collapse
Affiliation(s)
- A. C. Boos
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
- Dermatology and Allergy; Ludwig Maximilian University; Munich Germany
| | - B. Hagl
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - A. Schlesinger
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
- Dermatology and Allergy; Ludwig Maximilian University; Munich Germany
| | - B. E. Halm
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - N. Ballenberger
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - M. Pinarci
- Dermatology and Allergy; Ludwig Maximilian University; Munich Germany
| | - V. Heinz
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - D. Kreilinger
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - B. D. Spielberger
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - L. F. Schimke-Marques
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - J. Sawalle-Belohradsky
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - B. H. Belohradsky
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - B. Przybilla
- Dermatology and Allergy; Ludwig Maximilian University; Munich Germany
| | - B. Schaub
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| | - A. Wollenberg
- Dermatology and Allergy; Ludwig Maximilian University; Munich Germany
| | - E. D. Renner
- University Children's Hospital at Dr. von Haunersches Kinderspital; Ludwig Maximilian University; Munich Germany
| |
Collapse
|
7
|
Wollenberg A, Seba A, Antal AS. Immunological and molecular targets of atopic dermatitis treatment. Br J Dermatol 2014; 170 Suppl 1:7-11. [PMID: 24720588 DOI: 10.1111/bjd.12975] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2014] [Indexed: 01/20/2023]
Abstract
Atopic dermatitis (AD) is a common, chronic inflammatory skin disease with a highly variable clinical phenotype and heterogeneous pathophysiology. Its pathogenesis is associated with alterations to both the skin barrier and the immune system, which may in turn be influenced by genetic mutations and the patient's environment. Basic and translational research, as well as clinical trials, have helped broaden our knowledge of the molecular mechanisms underlying the development of AD and to identify potential treatment targets and approaches. These include new ways of reducing transepidermal water loss and the shedding of corneocytes, new ways of interacting with established molecular targets (such as histamine receptors and interleukins and other T-cell cytokines), and the identification of new molecular targets (such as toll-like receptors and tight junction proteins). Well-established treatment options such as emollients, corticosteroids and topical calcineurin inhibitors will clearly continue to have a role in treating AD. Among the new agents that could be joining them in the near future are sphinganin (a precursor of ceramides 1 and 3), cannabinoids, highly targeted monoclonal antibodies and subcutaneous immunotherapy.
Collapse
Affiliation(s)
- A Wollenberg
- Department of Dermatology and Allergy, Ludwig Maximilian University, Frauenlobstr. 9-11, D-80337, Munich, Germany
| | | | | |
Collapse
|
8
|
Affiliation(s)
- S. Weidinger
- Department of Dermatology, Venerology and Allergy; University Hospital Schleswig-Holstein; Campus Kiel
| | - N. Novak
- Department of Dermatology and Allergy; University of Bonn; Germany
| |
Collapse
|
9
|
Abstract
Systemic therapy for atopic dermatitis (AD) is indicated in patients with severe disease refractory to adequate topical treatment. Currently available drugs aim to decrease inflammation by suppressing and/or modulating immune responses and thus may indirectly improve skin barrier function, resulting in a decrease in clinical signs and symptoms in particular pruritus. Before considering systemic treatment, patient adherence to topical treatment including skin care has to be ensured. The selection of the drug depends on the disease severity, localization, complications, concomitant diseases, and age of the patient, but also on their availability and costs as well as the doctor's experience. Bearing in mind the potential risk of resistance, systemic therapy with antibiotics should be exclusively considered in clinically manifest infections such as in children. Here, we review recently published clinical trials and case reports on systemic therapy of pediatric and adult patients with AD to draw conclusions for clinical practice. Although AD is a common disease, controlled clinical studies investigating the efficacy of systemic drugs are scarce, except for cyclosporine, which has been approved for the therapy of severe AD.
Collapse
Affiliation(s)
- D. Simon
- Department of Dermatology; Inselspital; Bern University Hospital; University of Bern; Bern Switzerland
| | - T. Bieber
- Department of Dermatology and Allergy; University of Bonn; Bonn Germany
| |
Collapse
|
10
|
Wollenberg A, Feichtner K. Atopic dermatitis and skin allergies - update and outlook. Allergy 2013; 68:1509-19. [PMID: 24410780 DOI: 10.1111/all.12324] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/12/2013] [Indexed: 12/20/2022]
Abstract
During the last few years, an impressive amount of experimental studies and clinical trials have dealt with a variety of distinct topics in allergic skin diseases - especially atopic dermatitis. In this update, we discuss selected recent data that provide relevant insights into clinical and pathophysiological aspects of allergic skin diseases or discuss promising targets and strategies for the future treatment of skin allergy. This includes aspects of barrier malfunction and inflammation as well as the interaction of the cutaneous immune system with the skin microbiome and diagnostic procedures for working up atopic dermatitis patients. Additionally, contact dermatitis, urticaria, and drug reactions are addressed in this review. This update summarizes novel evidence, highlighting current areas of uncertainties and debates that will stimulate scientific discussions and research activities in the field of atopic dermatitis and skin allergies in the future.
Collapse
Affiliation(s)
- A. Wollenberg
- Department of Dermatology and Allergy; Ludwig Maximilian University; Munich Germany
| | - K. Feichtner
- Department of Dermatology and Allergy; Ludwig Maximilian University; Munich Germany
| |
Collapse
|